In this article, we are going to take a look at where Vir Biotechnology ... stocks year-to-date in the $1 billion to $5 billion market capitalization bracket. Stocks that I have covered this ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc.

HC Wainwright reaffirmed their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report report published on Friday morning,Benzinga reports. They currently have a $110 ...

One chart encapsulates why mega-cap tech stocks have dominated the broader stock market over the past few years. Goldman Sachs this week provided this striking chart, which measures the trailing ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Vir Biotechnology (VIR – Research Report) yesterday and set a price target of $14.00. The company’s shares closed ...

Shares of Vir Biotechnology (NASDAQ:VIR) climbed ~42% in the premarket on Wednesday after the company posted initial Phase 1 data for two antitumor agents developed using its PRO-XTEN masking ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

After hours: January 31 at 7:57:24 PM EST Loading Chart for VIR ...